Skip to main content
NEUROTECH INTERNATIONAL LIMITED logo

NEUROTECH INTERNATIONAL LIMITED — Investor Relations & Filings

Ticker · NTI ISIN · AU000000NTI9 ASX Professional, scientific and technical activities
Open in API
Filings indexed 667 across all filing types
Latest filing 2022-07-07 Regulatory Filings
Country AU Australia
Listing ASX NTI

About NEUROTECH INTERNATIONAL LIMITED

https://neurotechinternational.com/

Neurotech International Limited is a clinical-stage biopharmaceutical company focused on the development and commercialization of novel therapeutics for neurodevelopmental and neurological disorders. The company specializes in neuroprotective therapies, primarily targeting pediatric conditions with significant unmet medical needs, including Autism Spectrum Disorder (ASD), Pediatric Autoimmune Neuropsychiatric Disorders Associated with Streptococcal Infections (PANDAS), and Pediatric Acute-onset Neuropsychiatric Syndrome (PANS). Its lead drug candidate, NTI164, is a proprietary, broad-spectrum cannabinoid formulation derived from a unique cannabis strain. NTI164 is engineered to exert anti-inflammatory and neuroprotective effects by modulating neuroinflammatory pathways. The company conducts clinical trials to establish the safety and efficacy of its treatments, aiming to provide transformative behavioral and functional improvements for patients.

Recent filings

Filing Released Lang Actions
BREAKTHROUGH RESULTS WITH NTI164 IN PAEDIATRIC ASD 14 pages 345.5KB
Regulatory Filings Classification · 95% confidence The document is an ASX announcement dated 8 July 2022, detailing breakthrough clinical trial results for a medicinal cannabis product (NTI164) in pediatric Autism Spectrum Disorder (ASD). It includes detailed study design, safety and efficacy results, regulatory pathway updates, and a board appointment. The content is focused on announcing clinical trial outcomes and company developments rather than providing a full financial report or regulatory filing. The document is lengthy (15,000 characters) and contains substantive information about the clinical trial results and company updates, but it is not a formal financial report, audit report, or regulatory filing. It is an announcement of clinical trial results and company news, which fits best under the category of a Regulatory Filing (RNS) as it is a general regulatory announcement and does not fit other specific categories like Earnings Release or Annual Report. There is also a mention of a conference call to follow, but no transcript is included, so it is not a Call Transcript. The document also includes a board appointment, but the primary focus is on clinical trial results and regulatory updates, so it is not solely a Board/Management Information filing. Therefore, the best classification is Regulatory Filings (RNS).
2022-07-07 English
Reinstatement to Official Quotation 1 page 424.3KB
Regulatory Filings Classification · 95% confidence The document is a market announcement from ASX regarding the reinstatement to official quotation of Neurotech International Limited's securities following the release of a clinical study announcement. It is a brief regulatory announcement about trading status and compliance, not a financial report or detailed filing. The document length is short (726 characters), and it does not contain financial data or detailed report content. Therefore, it fits best under Regulatory Filings (RNS) as a general regulatory announcement.
2022-07-07 English
Investor Webinar 1 page 102.1KB
Investor Presentation Classification · 95% confidence The document is an ASX announcement dated 8 July 2022 about an upcoming live investor webinar hosted by the CEO of Neurotech International Limited. It provides details about the webinar format, timing, and topics to be discussed, including clinical trial results. The document does not contain any financial statements, detailed financial data, or comprehensive report content. It is a communication aimed at investors to present information and updates, typical of an investor presentation. The document length is short (2642 characters), and it is not a report publication announcement or a regulatory filing. Therefore, the most appropriate classification is Investor Presentation (IP).
2022-07-07 English
Investor Presentation 18 pages 16.4MB
Investor Presentation Classification · 95% confidence The document is a detailed presentation focused on the results of a Phase I/II clinical trial for a biopharmaceutical company, Neurotech International Limited. It includes a webinar agenda, trial outcomes, capital structure, product differentiation, development timelines, and executive team information. The content is structured as a presentation with slides and speaker notes, including forward-looking statements and disclaimers typical of investor communications. There is no indication that this is a regulatory filing, annual or interim report, earnings release, or other formal financial report. The document is clearly intended for investors and stakeholders to provide detailed information on clinical trial results and company strategy. Therefore, the document best fits the category of an Investor Presentation (IP). The document length (15,000 characters) and detailed content support this classification with high confidence.
2022-07-07 English
Extension to Voluntary Suspension 1 page 69.8KB
Regulatory Filings Classification · 95% confidence The document is a letter addressed to the Australian Securities Exchange requesting an extension to a voluntary suspension of trading in the company's securities. It mentions the reason for the suspension extension is pending an announcement about clinical study results. The document is short (1506 characters) and is a formal request related to trading status, not a financial report or announcement of financial results. It does not contain financial data, audit information, or management discussion. It is a regulatory communication about trading suspension status, which fits best under Regulatory Filings (RNS) as a general regulatory announcement that does not fit other specific categories.
2022-07-06 English
Suspension from Official Quotation 2 pages 491.6KB
Regulatory Filings Classification · 95% confidence The document is a market announcement from Neurotech International Limited regarding a voluntary suspension of its securities from official quotation on the ASX. It is a request for a trading halt pending the release of an announcement about clinical study results. The document does not contain financial data, management discussion, or detailed report content. It is a regulatory announcement related to trading status rather than a financial report or detailed corporate filing. Therefore, it fits best under Regulatory Filings (RNS), which is the fallback category for miscellaneous regulatory announcements that do not fit other specific categories.
2022-07-05 English

Browse filings by year

11 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.